Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
FAQ
- What is Taysha Gene Therapies, Inc.'s D&A?
- Taysha Gene Therapies, Inc. (TSHA) reported D&A of $400K in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s D&A changed year-over-year?
- Taysha Gene Therapies, Inc.'s D&A increased by 33.3% year-over-year, from $300K to $400K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s D&A?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s D&A has grown at a 19.8% compound annual growth rate (CAGR), from $526K to $1.08M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Taysha Gene Therapies, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude